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Introduction
The World Health Organisation 
(WHO) has defined probiotics as ‘live 
microorganisms which when administered in 
adequate amounts confer a health benefit 
on the host’.1 Most often, the bacteria 
come from two groups, Lactobacillus 
or Bifidobacterium. Within each group, 
there are different species (for example, 
Lactobacillus acidophilus and Bifidobacterium 
bifidus), and within each species, different 
strains (or varieties).2  Locally as in the rest 
of Europe, probiotics are available in foods 
such as milk, yoghurts and butter, combined 
with vitamins and minerals or sold alone.  
In recent years consumption of probiotics 
has been attributed to a multitude of 
benefits ranging from the treatment of 
diarrhoea to anticancer effects. Although 
such claims are in abundance, evidence 
from clinical trials to support such claims is 
lacking. 
Probiotics:
which, when and why?
The normal gut microflora, aside from aiding digestion, provides 
protection against pathogenic organisms. Probiotics have been 
manufactured with the idea of maximising the effect of gut 
microflora, also known as “good bacteria”, thus reducing the risk of 
infection. This theory has proved scientists right on several occasions 
however stronger evidence is necessary to establish the efficacy, 
safety and cost-effectiveness of these products. 
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Claim	1:	Prevention	
and	treatment	of	diarrhoea
a) Treatment of Clostridium difficile-
associated colitis in adults
	 	 Mechanism: probiotics restore the 
microbial balance of the gastrointestinal 
tract altered by infection with C. difficile.
	 	 Studies: Four studies have evaluated 
the use of probiotics in conjunction 
with conventional antibiotics (e.g. 
metronidazole and vancomycin) for the 
treatment of recurrence or an initial 
episode of C. difficile colitis in adults. 
Only one study has demonstrated 
significant benefits in patients receiving 
S. boulardii.3
	 	 Conclusion:	The evidence to support 
the use of probiotics with conventional 
treatment for C. difficile colitis is scanty 
and there is no evidence at all to support 
the use of probiotics as monotherapy for 
the treatment of C. difficile colitis. 
b) Probiotics for the prevention of antibiotic-
associated diarrhoea (AAD)
	 	 Mechanism: antibiotics alter 
the microbial balance within the 
gastrointestinal tract and probiotics work 
via restoration of the gut microflora. It 
is also thought that probiotics release 
inhibitory substances that stall the 
growth of pathogenic bacteria responsible 
for the diarrhoea.
	 	 Studies: there are ten studies 
conducted on around 2000 children who 
were receiving short-term probiotics co-
administered with antibiotics to prevent 
AAD. These trials included treatment 
with various probiotics including 
Saccharomyces boulardii, Lactobacilli 
spp. and Bifidobacterium spp. Results 
of these studies show statistically 
significant results favouring probiotics 
over controls.4 There are only two small 
studies conducted in adults, and only one 
of these utilising the Lactobacillus strain 
has shown some efficacy.
	 	 Conclusion:	Although results are very 
promising, the routine use of probiotics 
for the prevention of paediatric AAD is 
not recommended until further trials 
determine the strain and dose required.4 
In adults the evidence is very limited 
because the group sizes of the trials were 
small and significant effects could have 
been missed.
c) Traveller’s diarrhoea
	 	 Mechanism:	probiotics restore the gut 
flora.
	 	 Studies:	three studies investigated 
whether Lactobacillus strains can prevent 
traveller’s diarrhoea. In one of the 
studies treatment with probiotics reduced 
the incidence of diarrhoea significantly 
from 40% to 24%. In the other study 
the incidence of diarrhoea was not 
statistically significant between the 
probiotic group and the placebo group. 
A double-blind placebo controlled study 
using L. acidophilus strains showed no 
difference in the incidence of traveller’s 
diarrhoea.
	 	 Conclusion:	the effect of probiotics 
on the incidence of traveller’s diarrhoea 
seems to depend on the bacterial stain 
and the destination of the travellers and 
needs further study. 
Issue 14 Summer 2008   Journal of the Malta College of Pharmacy Practice    1
d) Diarrhoea caused by rotavirus
	 	 Mechanism:	rotavirus infection 
causes gastroenteritis characterised by 
acute diarrhoea and vomiting and is 
a leading cause of death and disease 
among children worldwide. Probiotics 
are thought to restore the gut microflora 
following rotavirus infection. 
	 	 Studies:	Several studies have shown 
that consumption of Lactobacillus GG 
shortened the duration of diarrhoea 
from . to 2. days in children. B. 
bifidum and S. thermophilus, also 
reduced the incidence of diarrhoea in a 
double-blind, placebo-controlled trial 
in  hospitalised infants. Studies 
with Enterococcus species also showed 
beneficial effects however L. acidophilus 
failed to show significant differences in 
recovery times in diarrhoea caused by 
rotavirus.
	 	 Conclusion:	The strongest evidence 
for shortening of the diarrhoeal phase 
of rotavirus infection was with the 
consumption of Lactobacillus GG.2,
Claim	2:	Treatment	of	Helicobacter	
pylori	Infection
Mechanism:	Probiotics may compete 
directly with H. pylori, possibly through the 
inhibition of adherence, as well as produce 
metabolites and antimicrobial molecules 
such as bacteriocins, which inhibit H. pylori 
growth. Only animal and in vitro data has 
supported these properties.2 
Studies:	Seven of nine human studies 
showed an improvement of H. pylori 
gastritis and decrease in H. pylori density 
after administration of probiotics.6 The 
addition of probiotics to standard antibiotic 
treatment improved H. pylori eradication 
and reduced treatment associated side 
effects. This success however seems to be 
attributed to the fact that more patients 
completed the eradication treatment rather 
than because of eradication H. pylori 
infection by probiotic treatment alone.6-8
Conclusion:	Based on current data, 
even though an effect against H. pylori 
has been described, probiotics cannot be 
considered as an alternative to standard 
anti-H. pylori treatment. Nevertheless, their 
use in association with standard anti-H. 
pylori treatment may be advisable, as they 
are able to improve patient compliance by 
reducing antibiotic-related adverse events, 
thus increasing the number of patients 
completing the eradication therapy.
Claim	3:	Managing	Lactose	Intolerance
Mechanism: microbial β-galactosidase 
in live yoghurt hydrolyses lactose allowing 
better digestion and absorption of glucose 
and galactose thus reducing the symptoms 
associated with lactose intolerance.2,9,10 
Studies: A large number of human 
studies in which consumption of fresh 
yoghurt with live cultures was compared 
with consumption of a pasteurised product 
with heat killed bacteria demonstrated 
better lactose digestion and absorption 
as well as reduction of gastrointestinal 
symptoms with the fresh yoghurt.2 The 
efficacy of probiotics is dependent on 
the ability of lactobacilli to release β-
galactosidase and this is limited by the 
fact that not all lactobacilli have the same 
ability to release this enzyme.2,10
Conclusion: Some probiotics maybe 
effective in alleviating the signs and 
symptoms of this condition, although 
further trials of specific strains and 
concentrations are necessary.
Claim	4:	Lowering	of	blood	cholesterol
Mechanism: Probiotic bacteria ferment 
food-derived indigestible carbohydrates to 
produce short-chain fatty acids in the gut, 
which can then cause a decrease in the 
systemic levels of blood lipids by inhibiting 
hepatic cholesterol synthesis and/or 
redistributing cholesterol from plasma to 
the liver. Other bacteria may interfere with 
Table	1.	Summary	of	evidence	for	the	use	of	probiotics
Claim Evidence
Prevention of Clostridium difficile-associated colitis in adults No evidence for monotherapy with probiotics
Prevention of antibiotic-associated diarrhoea Evidence limited but very promising
Prevention of traveller’s diarrhoea Insufficient evidence
Treatment of diarrhoea caused by rotavirus Strong evidence especially in paediatrics
Treatment of Helicobacter pylori infection Good evidence for use in conjunction with standard anti-H.pylori treatment
Managing lactose intolerance Strong evidence in favour of probiotics in alleviating signs and symptoms of lactose malabsorption
Lowering of blood cholesterol Insufficient evidence
Treatment of vaginal infections Insufficient evidence
Anticancer effects Insufficient evidence
Management of inflammatory bowel disease
Good evidence for pouchitis and maintenance of remission 
but larger trials are needed to assess their value in other 
inflammatory bowel disorders
Prevention and treatment of atopic diseases Strong evidence for probiotic use in high risk infants
Enhancement of the immune function Strong evidence for shortening duration of common colds
Prevention of preterm labour Insufficient evidence
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cholesterol absorption from the gut.11
Studies: In 194 a paper published in 
the American Journal of Clinical Nutrition 
reported that consumption of probiotics in 
the form of fermented milk was associated 
with reduced serum cholesterol in the 
Maasai people.12 Other studies in 190’s 
have utilised inadequate sample sizes and 
excessive quantities of the product thus 
producing equivocal findings.1 More recent 
studies, which are of better quality with 
redesigned standards, have failed to provide 
convincing and consistence evidence that 
strains of L acidophilus and L. bulgaris 
have lowering-cholesterol efficacy in man. 
A meta-analysis of controlled short-term 
studies has shown that consumption of 
yoghurt containing Enterococcus faecium is 
effective in reducing both total and low-
density lipoprotein (LDL) cholesterol by 4% 
and % respectively. Whether the effects are 
sustained over time remains to be proven.2 
Consumption of food products containing L 
plantarum 299v has also been reported to 
lower total and LDL cholesterol in subjects 
with moderately raised cholesterol levels. 
Additionally subjects consuming 200ml of 
milk fermented with L casei TMC0409 and 
S thermophilus TMC 14 daily showed 
significant increases in high density 
lipoprotein after four and eight weeks of 
supplementation.2 
Conclusion: The lasting effect of 
probiotics on serum cholesterol is 
inconclusive.
Claim	5:	Treatment	of	vaginal	infections
Mechanism:	lactic acid bacteria 
predominate in the normal vaginal flora, 
generating an acidic pH, which inhibits the 
growth of other organisms that can cause 
vaginal infections.9
Studies:	Over the years there have 
been a number of clinical trials evaluating 
the ability of orally or intravaginally 
administered lactobacilli to inhibit the 
vaginal colonization by yeasts and prevent 
the recurrence of vulvovaginal candidiasis. 
In most of these studies the difference 
in risk of developing vaginal candidiasis 
in patients on probiotics compared to 
those who took placebo was small and not 
significantly different. Additionally a study 
investigating the use of lactobacilli in the 
prevention of post-antibiotic vulvovaginitis 
failed to show any significant advantage 
of using probiotics in conjunction with 
antibiotics.14 
Conclusion:	Although several studies 
have shown that oral consumption of 
probiotics can alter vaginal microflora, most 
of these had either a flawed methodology 
or a very small sample size thus 
providing limited evidence to support the 
effectiveness of probiotic preparations. 
Claim	6:	Anticancer	effects
Mechanism: regular, long-term 
consumption of probiotics has been 
suggested to protect against bowel cancer. 
The basis for this is that the acid pH in 
the colon generated by probiotics could 
inhibit the transformation of procarcinogen 
to active carcinogens	and reducing the 
absorption of mutagens from the intestine.9 
Studies:	consumption of probiotics 
(Lactobacillus salivarius) has been 
associated with a reduced incidence of 
colonic adenocarcinoma in mice. Other 
studies in animal models have also shown 
probiotics to reduce intestinal inflammation, 
which has been associated with an 
increased incidence of colorectal cancer. 
Human studies have demonstrated the 
ability of probiotics to decrease the activity 
of some bacterial enzymes, which play an 
important role in cancer development as 
they hydrolyse carcinogenic compounds.2,,1 
Conclusion:	Large-scale trials are still 
required to support the implications of 
probiotics in the field of colorectal cancer. 
Claim	7:	Management	of	
inflammatory	bowel	disease
Mechanism:	it is claimed that patients 
with inflammatory bowel disease such as 
Crohn’s disease and ulcerative colitis may 
have an abnormal gut microflora in terms 
of both the organisms and their ability 
to adhere to the gut wall.9 Probiotics 
can potentially reduce the population of 
abnormal bacteria and reverse any problems 
of adhesion. Additionally probiotics may 
help to improve gut immune function.2,9
Studies: A recent systematic review in 
ulcerative colitis concluded that significant 
difference in effectiveness have been 
reported for different types of strains in 
species of bacteria and yeasts and it seems 
that Bifidobacteria are likely to give the 
best results.16 There is some degree of 
evidence that probiotics added to standard 
therapy may provide modest reduction of 
disease activity in patients with mild to 
moderately severe ulcerative colitis.16,1
Seven small studies have investigated 
the use of probiotics in the induction 
or maintenance of remission in Crohn’s 
disease. One of the probiotics investigated 
was VSL# a patented combination of eight 
probiotic strains, including bifidobacteria 
and lactobacillus. Although outcomes 
have included an increase in relapse free 
time and a reduction in inflammation 
such differences were not statistically 
significant.18
Conclusion:	Larger trials are needed 
to assess whether the use of probiotics 
can reduce the relapse of inflammatory 
bowel disease and/or maintain patients 
in remission and to see whether they are 
safer than the traditional anti-inflammatory 
drugs. 
Claim	8:	Prevention	and	treatment	
of	atopic	diseases
Mechanism:	it is thought that 
optimising gut flora might reduce the risk 
of allergic disease by preventing increase 
in gut permeability associated with 
infection or by stimulating anti-allergic 
immunological responses. 
Studies:	A randomised double blind, 
placebo-controlled trial carried out in 4 
infants showed no significant benefit for 
the use of probiotic bacteria in infants 
with atopic dermatitis. In another similar 
study 1,2 pregnant women and their 
babies were evaluated for the cumulative 
incidence of allergic diseases (eczema, 
asthma, allergic rhinitis and food allergies). 
Probiotic treatment compared with placebo 
showed no effect on the cumulative 
incidence of allergic diseases by age 2 
years but significantly prevented eczema 
especially atopic eczema.19
Conclusion: the prevention of atopic 
eczema in high-risk infants seems possible 
by modulating their gut miroflora of infants 
with probiotics.19 
Claim	9:	Enhancement	
of	the	immune	function
Mechanism: Specific strains of lactic 
acid bacteria, when consumed in sufficient 
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•	Probiotics should not be taken with hot beverages. Temperatures above 0oC 
denature the bacteria rendering the product ineffective.
•	There is limited evidence supporting some uses of probiotics. 
 Much more scientific knowledge is needed about probiotics, 
 including about their safety and appropriate use.
•	Effects found from one species or strain of probiotics 
 does not necessarily hold true for others.
•	Immunocompromised patients should not be exposed to probiotics, 
 as safety in this group of patients has not yet been established.
Practice	Pointsnumbers are able to alter some aspects of 
natural and acquired immune responses. 
Studies: A recent double blind 
randomised controlled trial has studied 49 
healthy adults during two winter/spring 
periods. The patients were supplemented 
with a daily preparation of vitamins 
and minerals with or without probiotics 
lactobacilli and bifidobacteria. Whilst the 
intake of the probiotic had no effect on the 
incidence of common colds, it significantly 
shortened common cold episodes and 
reduced the severity of symptoms.20 
Conclusion:	A three-month consumption 
of probiotics may reduce the severity of 
common colds and reduce the duration by 
almost 2 days.20
Claim	10:	Probiotics	
for	preventing	preterm	labour
Mechanism:	0% to 0% of pregnant 
females who go into labour too soon were 
found to have an infection and it is thought 
that this is what stimulates labour.21 
Studies: there have been two trials 
involving a total of 108 women. In one trial 
the probiotics were given orally whereas 
the other utilised yoghurt used vaginally by 
women diagnosed with bacterial vaginosis 
in early pregnancy. Pooled results showed 
an 81% reduction in the risk of genital 
infection with the use of probiotics.21
Conclusion:	although probiotics appear 
to treat vaginal infections in pregnancy 
there is currently insufficient evidence to 
justify the use of probiotics to reduce the 
risk of preterm birth.21,22
Adverse	Effects	
Probiotics are generally considered to be 
safe with side effects if any being mild and 
digestive such as bloating.9 However some 
probiotic species have been rarely isolated 
from infectious sites although these appear 
mainly in patients with serious underlying 
diseases and/or immunosuppression.2 
They could also cause unhealthy metabolic 
activities such as over-stimulation of the 
immune system.2 
Conclusion
It is expected that in the future, new, 
well characterised, scientifically proven 
probiotic strains with specific health benefits 
will be developed. In addition, further well-
designed clinical trials should provide health 
care professionals with sufficient evidence 
for the rational use of probiotics. 
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